The cure rate of the cancer vaccine of the US cancer vaccine 97% human trials is still unknown

category:Hot
 The cure rate of the cancer vaccine of the US cancer vaccine 97% human trials is still unknown


According to the reporters enquiry, the website of Stanford University medical school reported the results of the study. The report shows that the cure rate of the vaccine in rats is 97%, and it is expected that human trials will be carried out this year. A needle makes cancer cells disappear completely A shot can let the patients whole body cancer cells completely disappear, this should be all the cancer patients and their families dream to see. At the beginning of the article exploding money, the success rate of cancer vaccine research and development in the United States has reached 97%, the author told the netizens this dream is coming to reality. After the publication of the article, it caused the Internet users and the industry to pay attention to it. As of yesterday, the volume of reading has exceeded 100 thousand + 30 thousand times, and has been forwarded by several self media official numbers. There are many professional figures in the medical field. The reporter noticed that WeChat public number of sixth hospital in Xiangtan, Hunan province also forwarded the article. In other media articles, this research is more exciting. New cancer vaccines have been eliminated in 97% years, and no side effects have been achieved in the past 1 years. A netizen commented, if this is successful, the treatment of cancer is the same as the treatment of a cold. 15 patients will be recruited for clinical trials Yesterday, the new Beijing News reporter found the news of the research results at the Stanford University medical school official website. In the article cancer elimination vaccine can eliminate mouse tumor (Cancervaccineeliminatestumorsinmice), RonaldLevy, Professor of oncology, Stanford University School of medicine, introduced the research process and results. According to well-known cancer science writer pineapple, RonaldLevy is a fellow of the American Academy of Sciences, is one of the earliest known as cancer antibody therapy, because his research leads directly to the target immune to drug rituximab treatment of lymphoma. The results of the study were published in January 31st of this year. The content of this article shows that in this study, researchers transplanted two lymphoma tumors in different parts of mice, and injected two trace immunostimulants directly into one of the tumors to activate T cells in the tumor (one of the human immune cells). When we use these two drugs at the same time, the mices whole body tumor subsided. The researchers reported that after the injection of the cancer vaccine, all the tumors in the mice were removed, including another uninjected shift. Of the 90 mice tested, 87 of the cancer cells were removed, the researchers said. Although 3 mice had a recurrence of the tumor, the tumor was eliminated after second treatments. The researchers also saw similar results in mice with breast, colon and melanoma. Referring to the advantages of this method, RonaldLevy said that a small amount of such drugs can be used as a fast and relatively inexpensive way of cancer treatment, and it is unlikely to cause any side effects of systemic immune stimulation. Reporters noted that the study has not yet carried out large-scale clinical trials, the research group said that at the end of this year, 15 low-grade lymphoma patients will be recruited for trial. If the test is successful, the method will be tested on more patients with different types of cancer. On the 1 is major medical breakthrough? Part of the innovation based on the traditional research method is not a major breakthrough Both CpG and OX40 antibodies were used in the previous tumor immunotherapy, but they used to be used alone, and the researchers combined the two for the first time. In addition, the test used local injection in the tumor, which is different from the previous intravenous administration. From Wang Yuedans point of view, from the perspective of scientific research, the local vaccine injection method of OX40 antibody +CpG proposed by researchers is based on some innovations in traditional research methods, and is not a major breakthrough. On 2 human trials of the success rate is very high? The mechanism of mice and human cancer is different, and the possibility of success is not very likely. Whether the test is successful or not is a question. I hope they will succeed in human experimentation, but there is little hope of success. If the test is successful and further expand the scope of the test, the possibility of replicating success is not significant. Wang Yuedan thinks its too early to say cancer vaccine can cure cancer. Real name authentication information is Stanford University medical school doctor micro-blog blogger @ Bao Ni yesterday also expressed doubts. She believes that a lot of experiments are successful on mice, which does not mean that they will be successful, especially cancer. First, there are many different mechanisms of cancer between mice and people, so there is a great difference in the immune response. Secondly, the size of human tumor is still different from that of mice. Therefore, many clinical studies found that the removal of tumor is not complete because of the difference between them. A well-known cancer science writer pineapple, also wrote that the research is still far away from clinical application. In addition to the species differences between mice and people, pineapple points out that human tumors are still heterogeneous. The tumor in human body usually evolved from 10 to 20 years ago. There are usually many tumors with different characteristics in each cancer patient at the same time. This phenomenon is called tumor heterogeneity. Because of the presence of heterogeneity, the anticancer drugs sometimes kill only 90% human cancer cells, not 100%, which leads to tumor resistance and recurrence. But the mouse tumor model used in the laboratory grew in a few weeks. There was no evolutionary process. The tumor cells came from a single source, not a variety of mixtures. As a result, once the drug works, it is easy to kill 99%, or even 100%, of the cancer cells. In this paper, the pineapple lashed out at the so-called American cancer vaccine research and development success is the title of the party, in his opinion, more accurate expression should be cancer vaccine in animal models on the effect is very good, dozens of little mice a little tumor disappeared. Polular Science The new cancer vaccine In fact, the so-called cancer vaccine is not new. Shanghai city disease prevention and control center said the immunization division director doctor, famous vaccine science writer Tao Lina told the Beijing News reporter to interview, the body always exists cancerous cells, an important function of the immune systems immune surveillance, identification of these bad cells and eliminate them. One of the key reasons why patients get cancer is the problem of immune surveillance. An important direction for the treatment of cancer is to restore the immune systems universal immune surveillance of all cancer cells. In fact, vaccines are divided into two kinds: preventive and therapeutic. Unlike popular vaccines, such as hepatitis B vaccine, cancer vaccine is a therapeutic vaccine. Wang Yuedan said that a universal vaccine, called a needle to eliminate all cancer cells, is actually a non specific vaccine. A specific vaccine is a vaccine directed to a specific antigen, such as hepatitis B vaccine, only against hepatitis B virus. Hepatitis B vaccine can not prevent poliomyelitis. In contrast, the non specific vaccine is not targeted, but the overall improvement of the bodys self immunity. In simple terms, its working principle is to mobilize the bodys own immune system to fight cancer and, instead of ourselves to kill the death of cancer cells. Unlike traditional surgical treatments such as surgical resection, chemotherapy and radiation therapy, the immune therapy that mobilizes the bodys immune system to enhance anti-tumor immunity is becoming a new trend of cancer therapy. In 2015, the food and Drug Administration approved the dendritic cell immunotherapy for metastatic prostate cancer. It is also the first cancer therapeutic vaccine in the world. Source of this article: the author of the new Beijing newspaper: Xu Wens responsibility editor: Li Hang _BJS4645 In fact, vaccines are divided into two kinds: preventive and therapeutic. Unlike popular vaccines, such as hepatitis B vaccine, cancer vaccine is a therapeutic vaccine. Wang Yuedan said that a universal vaccine, called a needle to eliminate all cancer cells, is actually a non specific vaccine. A specific vaccine is a vaccine directed to a specific antigen, such as hepatitis B vaccine, only against hepatitis B virus. Hepatitis B vaccine can not prevent poliomyelitis. In contrast, the non specific vaccine is not targeted, but the overall improvement of the bodys self immunity. In simple terms, its working principle is to mobilize the bodys own immune system to fight cancer and, instead of ourselves to kill the death of cancer cells. Unlike traditional surgical treatments such as surgical resection, chemotherapy and radiation therapy, the immune therapy that mobilizes the bodys immune system to enhance anti-tumor immunity is becoming a new trend of cancer therapy. In 2015, the food and Drug Administration approved the dendritic cell immunotherapy for metastatic prostate cancer. It is also the first cancer therapeutic vaccine in the world.